Global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment Market Overview
Benign prostatic hyperplasia (BPH) is the medical condition typically observed in old-aged men characterized by enlargement of the prostate gland resulting in squeezing of the urethra. BPH can cause problems in the urinary bladder, kidney, and urinary tract. It is often treated with prescribed doses of alpha-blockers, 5-alpha reductase, or a combination of other drugs. For severe conditions, minimally invasive or laser therapies are also performed. The number of men seeking treatment for benign prostatic hyperplasia (BPH) is expected to rise in the coming years due to the growing aging male population and the increasing prevalence of obesity, cardiovascular diseases, and erectile dysfunction. BPH is a common condition in aging men and the most common cause of lower urinary tract symptoms. The prevalence of BPH rises after 40 years, with a prevalence of 8% to 60% at age 90 years. As per United Nations, the number of older persons is growing faster than the younger age groups. The global population aged over 80 years is projected to triple, increasing from 137 million in 2017 to 425 million in 2050. Obesity affects the geriatric population in parallel to that of the general population. The prevalence of obesity in the older population has been rising and now poses a major global threat in developed and developing countries. All of these will contribute to the growing prevalence of BPH, thus therapeutics.
The global demand for benign prostatic hyperplasia (BPH) and prostate treatment market was valued at 10,584.19 USD MN in 2021 and is expected to generate revenue of 15,791.78 USD MN in 2028, growing at a CAGR of 5.62% between 2022 and 2028.
The rise in awareness regarding urological diseases contributes to the growth of the benign prostatic hyperplasia treatment market. The growing preference for advanced treatment such as transurethral resection of the prostate (TURP), transurethral incision of the prostate (TUIP), transurethral microwave therapy (TUMT), and other minimally invasive techniques are also projected to foster the market growth during the timespan. Even if BPH is treated with drugs and surgeries, it does come with some side effects. Common side effects include dizziness, orthostatic hypotension, retrograde ejaculation, and rhinitis. Surgeries' side effects include pain, problems urinating, and other infections. This may hinder the market growth.
The global benign prostatic hyperplasia treatment market is highly fragmented. Abbott Laboratories, Allergan plc, Astellas Pharma, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Boehringer Ingelheim Pharma GmbH & Co. KG, Merck & Co., Inc., Pfizer, Inc., Sanofi, and Teva Pharmaceutical Industries Limited are key players associated with the market. Key companies are adopting merger & acquisition strategies and joint ventures to gain a more significant share in the overall market. Several companies are spending in R&D for the exploration of better treatment.
In this research report, the global Benign Prostatic Hyperplasia (BPH) and Prostate Treatment market is segmented by therapy and region.
Analysis, By Type:
By type, the global benign prostatic hyperplasia therapeutics market is segmented into drugs and surgeries. The drug segment occupies a major share in 2021. Drugs alone are known to be more effective. Drug therapy is growing due to its high effectiveness, superior symptomatic benefit, and significant reduction in adverse events.
Analysis, By Surgical Treatment:
Among surgical treatments, Transurethral Resection of the Prostate holds the maximum share for the year 2021.
Analysis, By Drug Treatment:
Among drugs, the alpha-blocker segment acquired a major share in the market and is expected to stay dominant throughout the forecast period, owing to high preference, superior therapeutic action, and availability of many alpha-blocker drugs. Alpha-blockers work by relaxing the prostate and bladder neck muscle and allows urine to flow more easily. The surgeries segment is also projected to grow significantly due to the growing severity of the condition and failure of drug treatment.
Analysis, By End User:
By end user, the market is segmented into home-healthcare settings, hospitals, and clinics. Home healthcare is the largest shareholder on the basis of revenue for the year 2021.
Analysis, By Region
Geographically, the global benign prostatic hyperplasia treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is a dominant region in the global market, while the Asia-Pacific region is anticipated to grow faster during the forecast period. North America is expected to grow with the rising prevalence of benign prostatic hyperplasia, greater access to treatment. Also, the region is home to many market players and is blessed with skilled expertise. Asia Pacific growth is driven by factors including a high male population base, increased disposable income, and enhanced patient awareness about benign prostatic hyperplasia.
Market Segmentation covered in the Report:
By Surgical Treatment
- Surgical Treatment
- Drug Treatment
By Drug Treatment
- Transurethral Resection of the Prostate
- Transurethral Microwave Thermotherapy
- Transurethral Needle Ablation of the Prostate
- Laser Therapy
- Others (Prostatic Stenting, UroLift Therapy and Rezûm Therapy)
By End User
- Alpha Blockers
- 5-alpha Reductase Inhibitors
- Home Healthcare Settings
- Others (Hospitals & Clinics)
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.